Dermata Therapeutics, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Dermata Therapeutics performed this year. Think of this as a "cheat sheet" to help you decide if this company fits your investment goals.

1. What does this company do and how did they perform this year?

Dermata is a biotech company developing dermatology treatments. The big news this year is a major strategic shift. After finishing their Phase 3 trial for XYNGARI (an acne gel), the company decided that the cost to get FDA approval and launch the drug was too high. Instead, they are moving into the consumer skincare market. They plan to use their "Spongilla" technology to sell non-prescription, science-backed products, a path they believe is faster and more cost-effective than the traditional FDA approval process.

2. Financial performance

Because they are in the middle of this transition, the company is not yet profitable. For the year ending December 31, 2025, they reported a loss of about $8.2 million, primarily driven by research and administrative costs. They are currently spending about $500,000 to $600,000 in cash every month. As of March 2026, they had about 4 million shares outstanding. With a market value of roughly $3.1 million, this is a "micro-cap" stock, which makes the shares highly volatile and sensitive to bad news.

3. Major wins and challenges

• The Win: Their Phase 3 trial for XYNGARI was a success. The gel significantly reduced acne lesions compared to the control group, proving their Spongilla technology is effective.
• The Challenge: Taking a prescription drug to market would have cost over $50 million. Management decided this was too expensive for a small company, leading to the pivot toward consumer skincare to preserve cash and maintain operations.

4. Financial health

Dermata is in a high-stakes position with limited cash. They held about $1.5 million in cash as of their last report. This is not enough to fund operations for the next 12 months without raising more money. They have historically relied on private investors to bridge these gaps, which often involves issuing more shares. This dilutes existing ownership and can lower the value of your shares; in the last 18 months, the share count has jumped by over 40%.

5. Key risks that could hurt the stock price

• Execution Risk: The company has no prior experience in retail marketing or e-commerce. Moving from a lab-focused biotech model to a consumer brand requires a completely different set of operational skills.
• Dilution: Since they are not yet generating significant profit, they will likely need to raise more capital. This usually means issuing more shares, which lowers the value of your current holdings.
• Regulatory Hurdles: Even outside the drug-approval process, they must comply with FTC and FDA rules regarding skincare claims. If their marketing claims are perceived as drug-like, they could face costly legal trouble or be forced to rebrand their products.

6. Future outlook

The company is betting its future on its Spongilla skincare line. Over the next year, they aim to build online sales and partner with dermatologists. To evaluate their progress, watch their revenue growth and their customer acquisition costs. If they cannot generate enough sales to cover their $6 million in annual operating costs, they will face a serious cash crisis.

Investor Takeaway: Dermata is a high-risk, speculative play. You are essentially betting on their ability to successfully pivot from a clinical-stage biotech company to a consumer retail brand. Before investing, consider if you are comfortable with the high likelihood of further share dilution and the significant execution risks involved in their new business model.